FDA Grants Supplemental Approval for IBTROZI® in ROS1-Positive Lung Cancer

The FDA has granted supplemental approval for Nuvation Bio's IBTROZI® (taletrectinib) to treat TKI-naïve advanced ROS1-positive non-small cell lung cancer. This decision, based on updated duration of response data, reinforces the drug's efficacy and provides further evidence for its use, offering an important treatment option for this specific patient population.